A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A phase I clinical trial. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback